Cadrenal Therapeutics Inc. (CVKD)
NASDAQ: CVKDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CVKD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.01M
- EPS (TTM)
- -$3.67
- Dividend yield
- None
- 52-week range
- 0.816 – 12.50
- Day range
- 1.52 – 1.85
- Volume / Avg
- 206.57K / 496.14K
- Beta
- —
- Shares outstanding
- 4.12M
- Next earnings
- Nov 23, 2026
52-week range
CVKD stock today
Shares of Cadrenal Therapeutics (CVKD) finished higher on Nov 20 at $1.70, a gain of 0.59% or $0.01 per share, versus the S&P 500's 3.70% decline. Trading was light, with 206.57K shares changing hands, about 42% of the average daily volume. At this level, CVKD sits near the bottom of its 52-week range of $0.816 to $12.50: 86.4% below the high and 108.3% above the low.
Cadrenal Therapeutics has posted a net loss over the last twelve months (EPS of -$3.67), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 23; analysts expect EPS of -$0.91.
Summary generated from market data by MetaCap's automated system. Methodology
About Cadrenal Therapeutics
Company profileCadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Quang X. Pham
- Headquarters
- Ponte Vedra, FL
- Employees
- 5
- IPO year
- 2023
- Website
- cadrenal.com
Financial highlights
Full financialsCadrenal Therapeutics reported a net loss of $13.2 million, compared with a loss of $10.7 million a year earlier. Diluted earnings per share came in at -$6.64.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-13.24M | $-10.65M | $-8.36M |
| EPS (diluted) | $-6.64 | $-8.73 | $-9.29 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$14.00+723.53%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 23, 2026
- EPS estimate
- $-0.91
- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-1.31 vs $-0.91
- Surprise
- -43.96%
Cadrenal Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TCRTAlaunos Therapeutics Inc. | 1.66 | +3.75% | $6.99M | vs CVKD |
| ENSCEnsysce Biosciences Inc. | 0.36 | -0.17% | $7.00M | vs CVKD |
| CURXCuranex Pharmaceuticals Inc | 4.41 | -0.67% | $6.92M | vs CVKD |
| MTVAMetaVia Inc. | 1.01 | -7.34% | $6.81M | vs CVKD |
| IMRNImmuron Limited ADR | 0.8998 | +5.80% | $7.26M | vs CVKD |
| BFRGBullfrog AI Holdings Inc. | 0.3556 | -8.84% | $6.65M | vs CVKD |
| RKTORocket One Inc. | 0.297 | +5.24% | $7.39M | vs CVKD |
| VTGNVistagen Therapeutics Inc. | 0.1636 | -12.33% | $7.56M | vs CVKD |
Indexes, lists and sector
Cadrenal Therapeutics stock FAQ
What is Cadrenal Therapeutics's stock price today?
CVKD last traded at $1.70 as of Nov 20, 4:00 PM EST, up 0.59% on the day. Prices are delayed at least 15 minutes.
When is Cadrenal Therapeutics's next earnings date?
Cadrenal Therapeutics is expected to report earnings on Monday, November 23, 2026. Analysts expect EPS of $-0.91.
Who is Cadrenal Therapeutics's CEO?
Mr. Quang X. Pham is the chief executive officer of Cadrenal Therapeutics Inc., which has about 5 employees.
What is the CVKD 52-week high?
The 52-week high for CVKD is $12.50 and the 52-week low is $0.816. The stock is currently 86.4% below its high.